Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2026-01-01 @ 7:37 AM
Study NCT ID:
NCT02513550
Status:
COMPLETED
Last Update Posted:
2020-06-17
First Post:
2015-07-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
Sponsor:
Eli Lilly and Company
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module